This Cannabis Stock Got Destroyed in 2025. Can Trump Make 2026 a Different Story? Shares are down nearly 80% in 2025, but Trump signed executive order to reclassify marijuana. Barchart · Dec 25, 2025
Australian Psychedelics: Incannex Business & Financials, New Research Center For Mushrooms & Eating Disorders Clinical-stage biopharma company Incannex Healthcare Ltd. (NASDAQ: IXHL) shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several U.S. Benzinga · Oct 28, 2022
Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the space. Benzinga · Aug 19, 2022
Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A Benzinga · Jul 21, 2022
Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed an analysis of data from the Phase 2 proof-of-concept clinical trial invest Benzinga · Jun 3, 2022
Incannex Healthcare To Acquire APIRx Pharmaceuticals For $93.3M Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) announced that it has executed a term sheet with binding commercial terms to wholly acquire APIRx Pharmaceutical USA, LLC, subject to shareholder approval under ASX listing Rule 7.1. Benzinga · Mar 24, 2022
What's Going On With Incannex Healthcare's Stock Today? Incannex Healthcare Ltd (NASDAQ: IXHL) is soaring Tuesday on abnormally-high volume. Benzinga · Mar 15, 2022
Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients Incannex Healthcare Limited (NASDAQ: IXHL) has Benzinga · Mar 10, 2022
Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication… Benzinga · Mar 7, 2022
Psychedelics And Virtual Reality Treatment Developed By Monash University, Funded By Incannex Incannex Healthcare Limited (NASDAQ:IXHL) (ASX:IHL) has implemented a license agreement with Monash University to develop a novel treatment that combines virtual reality and psychedelics. This marks the initiation of a second clinical psychedelic therapy program. "We're delighted to have commenced this exciting project and to have expanded our partnership with… Benzinga · Mar 3, 2022
Medicinal Cannabis And Psychedelics Company Incannex Lists American Depositary Shares On Nasdaq Medicinal cannabis and psychedelics company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) commenced trading of its American Depositary Shares representing its ordinary shares on the Nasdaq Global Market under the ticker symbol 'IXHL'. Benzinga · Feb 28, 2022